Business Context and Reporting Period
This Form 8-K Current Report was filed by Boston Scientific Corporation on August 29, 2025. The filing addresses Item 5.02 regarding the departure of a senior officer and associated compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive personnel changes.
Material Changes
The primary material change reported is the announced retirement of Jeffrey B. Mirviss, Executive Vice President and President of Peripheral Interventions. His departure from the executive role is effective December 1, 2025.
Outlook, Management Commentary, and Risks
Transition Plan: Mr. Mirviss will transition to a senior advisor role immediately following his executive departure, continuing through February 27, 2026.
Compensation: During the senior advisor period, Mr. Mirviss will receive a prorated base salary of $705,000 annually. Upon the final retirement date, the Company expects to execute a Retirement Agreement providing benefits consistent with the Executive Retirement Plan, 2025 Annual Bonus Plan, and Long-Term Incentive Program.
Risks and Contingencies: The filing does not disclose specific financial risks or contingencies beyond the standard terms of the executive retirement agreement.
Investor Verification Checklist
- Verify the exact effective date of the leadership transition for the Peripheral Interventions division (December 1, 2025).
- Confirm the total duration of the senior advisor engagement (through February 27, 2026).
- Review the specific terms of the Executive Retirement Plan and 2025 Annual Bonus Plan referenced for final payout calculations.
- Monitor subsequent filings for the appointment of a successor to the President, Peripheral Interventions role.